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Abstract
Tuberculosis kills more people worldwide than any other infectious disease. Treatment
requires multiple drug therapy administered over long periods (6–24 months). The emer-
gence of multidrug-resistant strains is a major problem, and with few new drugs in the
pipeline, a novel modus operandi is urgently required. Solid drug nanoparticles (SDNs), a
new development in nanomedicine, offer a fresh therapeutic approach. Here, we show
that SDNs are more effective (50-fold) at killing pathogenic mycobacteria than aqueous
forms of the same drug and can target mycobacteria internalised by macrophages, where
bacilli reside. We demonstrate synthesis of dual and triple drug loaded SDNs, facilitating
combination tuberculosis therapy. Our results suggest that by employing SDNs of existing
antibiotics, it may be possible to improve drug delivery and therefore reduce drug dosage
to lessen side effects and ﬁght drug resistance.
Introduction
The use of nanoparticles (NPs) for drug delivery
systems is an expanding area of research (Vadakkan
et al. 2013; Pedrosa et al. 2014; Choudhary and Kusum
Devi 2015; Patel et al. 2013). The antimicrobial prop-
erties of some NPs are well documented (Donnellan
et al. 2015; Owens 2013; Neyrolles et al. 2013;
Bondarenko et al. 2012; Mohanty et al. 2013), offer in-
creased bioavailability (Pandey and Khuller 2005;
Mcdonald et al. 2014), and may allow targeted
treatment (Wang et al. 2014), and NPs show
promise against other diseases such as the human
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immunodeﬁciency virus (HIV) (Mcdonald et al. 2014;
Williams et al. 2015).
Solid drug nanoparticles (SDNs) are a novel deve-
lopment in nanotechnology (Mcdonald et al. 2014).
They are not a drug carrier system; they are nano-
sized amorphous particles, constructed of active phar-
maceutical ingredients (APIs) (Siccardi et al. 2016).
There are many advantages to creating excipient
stabilised nanoparticulate versions of FDA-approved
therapeutics, for example, they use existing APIs, thus
saving time and the exorbitant costs involved in novel
drug development and testing, they increase bioavail-
ability, and they may offer an opportunity to lower
treatment dose.
Tuberculosis (TB), caused by Mycobacterium tuber-
culosis (Mtb), kills up to 2 million people each year
with one third of the world’s population estimated to
have latent TB (WHO 2016). Drug-resistant strains
and the susceptibility to TB infection of HIV patients
heighten this global crisis, compounded by the
development of very few drugs in the past 40 years
(WHO 2014; WHO 2015; WHO 2016). Treatment periods
are very long (6–24 months) requiring multiple drug
administration, which is highly expensive and often
unsuccessful because of patient noncompliance.
Current treatment typically involves an initial four-
drug regimen: rifampicin (RIF), isoniazid (INH),
pyrazinamide (PZA), and ethambutol (WHO 2016;
Pandey and Ahmad 2011).
Herein, we describe the manufacture of anti-TB SDNs
and hypothesise that the delivery of existing antibiotics
in the form of SDNs would enhance toxicity to
mycobacteria and facilitate delivery to intracellular
compartments due to colocalisation following phago-
cytic uptake.
Experimental Section
Aqueous drug preparation
Rifampicin and INH were purchased from Sigma-
Aldrich® (Poole, UK) and prepared (and stored) follow-
ing product documentation. Stock solutions were stored
in tin-foil wrapped bottles at 4°C. From these stock
solutions, appropriate serial dilutions were made in
Middlebrook 7H9 broth for the desired concentrations.
SDN manufacture
Solid drug nanoparticles of ﬁrst line TB drugs were
prepared similarly to Mcdonald et al. (2014) as outlined
later. The incorporation of a ﬂuorescent dye (1,10-
dioctadecyl-3,3,30,30-tetramethylindodicarbocyanine,
4-chlorobenzenesulfonate salt (DiD)) to confer a ﬂuo-
rescent signal to each particle was included in some in-
cidences for imaging purposes. Both freeze and spray
drying methods were used, essentially producing the
same NP dispersions, while spray drying only was used
to scale up the samples as freeze drying could only pro-
duce relatively small quantities (up to 10 mg).
Preparation of emulsion-templated freeze-dried
monoliths containing 30% RIF nanoparticles (RIF SDN)
Stock solutions of RIF (30 mg/mL in dichloromethane
(DCM)), Pluronic F68® (22.5 mg/mL in water), and
Hyamine® (22.5 mg/mL in water) were prepared. The
three stock solutions were combined in the ratio
100:245:67 (μL) (RIF : Pluronic F68® : Hyamine®) plus
88-μL water. The ﬁnal solid mass ratio was therefore
30% RIF : 55% Pluronic F68® : 15% Hyamine® in a 1:4 DCM
to water mixture (total volume 0.5 mL). The sample was
emulsiﬁed using a Covaris S2x acoustic homogenisation
system for 30 sec with a duty cycle of 20, an intensity of
10, and 500 cycles/burst in frequency sweeping mode.
Immediately after emulsiﬁcation, the sample was cryo-
genically frozen and lyophilised using a Virtis benchtop
K freeze-drier for 48 h. The orange, dry, porous resultant
product was stored in the dark at room temperature.
Preparation of emulsion-templated freeze-dried
monoliths containing 29% RIF nanoparticles labelled
with 1% of the dye DiD (RIF SDN + DiD)
Preparation followed the same procedure as described
previously; however, a stock solution of 30-mg/mL DiD
was prepared. The four stock solutions were added to
a sample tube in the ratio 97:3:267:133 (μL)
(RIF : DiD : Pluronic F68® : Hyamine®) plus 88-μL water.
The ﬁnal solid mass ratio was therefore 29% RIF : 1%
DiD : 55% Pluronic F68® : 15% Hyamine® in a 1:4 DCM
to water mixture, with a total volume of 0.5 mL.
Preparation of emulsion-spray-dried 53% TRIPLE drug
powders containing RIF, INH, PZA (TRIPLE SDN)
A mass of 51.2-mg PZA, 20-mg RIF, and 8.8-mg INH were
weighed directly into a sample vial. A volume of 1-mL
DCM was then added and the powders mixed (inverted
and vortexed). Stock solutions of Kollicoat® Protect
(22.5 mg/mL in water) and Hyamine® (22.5 mg/mL in
water) were dissolved. The aqueous stock solutions
were added to the 1-mL API mix in DCM in the ratio
267:0.44 (mL) plus 0.89-mL water. The ﬁnal solid mass
ratio was therefore 34% PZA, 13% RIF : 6% INH : 40%
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Kollicoat® Protect : 7% Hyamine® in a 1:4 DCM to water
mixture (total volume 5 mL, 53% combined API). The
sample was emulsiﬁed using a Hielscher UP400S ultra-
sonic processor equipped with H7 Probe at 100% output
(22 W) for 15–20 sec. Immediately after emulsiﬁcation,
the sample was spray dried on a benchtop spray dryer
(BUCHI Mini-290) using an air-atomizing nozzle and com-
pressed air as the drying gas. Spray drying process condi-
tions were 5 mL/min solution ﬂow rate and 65°C outlet
temperature (120°C inlet temperature). The orange
powder was collected and stored in the dark at room
temperature.
Preparation of emulsion-spray-dried 52% TRIPLE drug
powders containing RIF, INH, PZA labelled with 1% of
the dye DiD (TRIPLE SDN + DiD)
Preparation followed the same procedure as described
previously; however, a stock solution of 53-mg/mL DiD
was prepared. A mass of 50.7-mg PZA, 19.8-mg RIF,
and 8.7-mg INH were weighed directly into a sample
vial. A volume of 97-mL DCM was then added and the
powders mixed. To this, 0.03 mL of DiD stock was
added. The aqueous stock solutions were added to
the 1-mL API mix in DCM in the ratio 267:0.44 (mL)
plus 0.89-mL water. The ﬁnal solid mass ratio was
therefore 33.7% PZA, 13% RIF : 6% IZH : 1% DiD : 40%
Kollicoat® Protect : 7% Hyamine® in a 1:4 DCM to
water mixture (total volume 5 mL, 52% combined
API, 1% DiD).
Preparation of emulsion-spray-dried 30% DUAL drug
powders containing RIF, INH
Preparation followed the same procedure as described
previously for the TRIPLE SDN; however, 40-mg RIF
and 20-mg INH were weighed directly into a sample
vial. Stock solutions of Kollicoat Protect® (45 mg/mL
in water) and Hyamine® (45 mg/mL in water) were dis-
solved. The aqueous stock solutions were added to the
1-mL API mix in DCM in the ratio 5.34-mL Kollicoat Pro-
tect® : 0.88-mL Hyamine® plus 1.78-mL water. The ﬁnal
solid mass ratio was therefore 20% RIF : 10% IZH : 60%
Kollicoat Protect® : 10% Hyamine® in a 1:4 DCM to water
mixture (total volume 5 mL, 30% combined API).
Powder X-ray diffraction
RIF SDNs were stored at 25°C in their powder, monolith
form for 1 month at 25°C. Analysis was carried out by
powder X-ray diffraction (p-XRD). p-XRD measurements
were collected in transmission mode on solid monolith
samples held on a thin Mylar ﬁlm in aluminium well
plates on a Panalytical X’Pert PRO MPD instrument with
X’PERT OPERATOR INTERFACE (version 1.0b) software.
SDN preparation and characterisation
All SDNs were sub sampled under sterile conditions and
kept in the dark at ambient temperature until use. SDNs
were diluted in sterile 2% (vol/vol) foetal calf serum
(prepared in sterile distilled water) at a concentration
of 1 mg/mL and vortexed and then placed on ice. SDNs
were then diluted in Middlebrook 7H9 broth supple-
mented with 10% (vol/vol) Middlebrook ADC enrich-
ment (albumin/dextrose/catalase (Becton Dickinson,
UK)), 0.2% (vol/vol) glycerol, 2-μg/mL mycobactin J
(7H9). Agglomeration status, Zeta potential, and hydro-
dynamic sizes were analysed by dynamic light scat-
tering (DLS) using plastic disposable cuvettes at an
SDN concentration of 100 μg/mL using a Zetasizer
Nano-ZS instrument (Malvern Instruments Ltd., UK).
Each sample was measured in triplicate.
Reporter strain of Mycobacteria
The Map K10/GFP strain transformed with a plasmid
carrying the gfp gene (and a kanamycin resistance
gene), which allows growth and viability to be tracked
with ﬂuorescence, was kindly provided by Professor
Raul Barletta, University of Nebraska, Lincoln (Harris
et al. 2002). Map K10/GFP was cultured in Middlebrook
7H9 broth supplemented with 10% (vol/vol)
Middlebrook ADC enrichment (albumin/dextrose/cata-
lase (Becton Dickinson, UK)), with 0.2% (vol/vol) glyc-
erol, 0.05% (vol/vol) Tween 80, 2-μg/mL mycobactin
J, and 25-μg/mL of kanamycin (7H9K+) at 37°C gently
stirred (250 rpm) continuously with magnetic stirrers.
Screening the antimicrobial properties of SDNs
The antimicrobial properties of SDNs and aqueous drugs
were screened using the previously described assay
(Donnellan et al. 2015). Brieﬂy, Map K10/GFP was
cultured in 7H9K+ until the exponential stage of
growth. Sterile, black, 96 well plates (Nunc, Thermo
Fisher) were seeded with Map K10/GFP (2 × 106
CFU/100 μL/well). The bacteria were then exposed to
SDNs and aqueous drugs in 7H9 at concentrations rang-
ing from 1.875 ng/mL to 4 μg/mL (ﬁnal 200 μL volume
per well) and incubated for up to 7 days at 37°C with
medium agitation (250 rpm) in the dark. Blank wells,
medium only (no bacteria, no SDN/drug) and
SDN/drug (no bacteria) were included as controls to
check for SDN/drug interference. Fluorescence was
measured using a GloMax® Multi+ plate reader
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(Promega, UK) (Ex/Em 490/510–570 nm). Bacterial ﬂuo-
rescence was monitored immediately after SDN/drug
addition (day 0), then at the same time each day for
7 days. All experiments were performed in triplicate,
a minimum of three times, under sterile conditions.
Data analysis
Results expressed in arbitrary ﬂuorescent units against
time (days) were transformed and normalised to obtain
a standard dose response relationship for comparison
between SDNs and aqueous RIF using a data analysis
protocol for screening the efﬁcacy of antimycobacterial
substances as previously described (Donnellan et al.
2015), where G is the ﬂuorescent units, G0 is the bacte-
rial growth at time 0, β is the growth rate (per day), and
t is the time (days).
Phage ampliﬁcation assay
Detection and enumeration testing was carried out
according to Rees and Botsaris (2012). Brieﬂy, to per-
form the phage ampliﬁcation assay, cell culture samples
(200 μL) was mixed with 800-μL Middlebrook 7H9 broth
supplemented with ADC and CaCl2 (2 mmol/L). Samples
(1 mL) containing mycobacteria were mixed with 1 × 108
mycobacteriophage D29 (100 μL) and incubated for 1 h.
Remaining extracellular phage were then inactivated
using a virucide treatment (100 μL 10 mmol/L ferrous
ammonium sulphate for 6 min). The virucide was then
neutralised by dilution using 5-mL Middlebrook 7H9
broth, and the phage-infected cells were plated in a
lawn of fast growing Mycobacterium smegmatis (1 mL,
107 cfu/mL) using soft agar (0.8% w/v). Lysis of the
infected cells at the end of the lytic cycle leads to the
formation of plaques in the lawn of M. smegmatis.
Because each plaque formed represents one myco-
bacterial cell in the original sample the assay can be
used to enumerate the mycobacterial cultures (data re-
ported as pfu/mL).
Cytotoxicity testing
Cytotoxicity of the SDNs on macrophages was assessed
using the Alamar Blue® assay, a cell viability test by
measuring mitochondrial activity. Macrophages (murine
macrophage cell line J744A.1) were cultured in 75cm2
T5 ﬂasks in complete medium (RPMI 1640 (Thermo
Fisher Scientiﬁc, UK) supplemented with 10% heat
inactivated foetal calf serum, 100-μg/mL streptomycin,
100-IU/mL penicillin, 0.1-mmol/L nonessential amino
acid, 1-mmol/L sodium pyruvate solution) and incu-
bated at 37°C, 5% CO2 until 95% conﬂuent. Cells were
harvested using a gentle scraping method under sterile
conditions and resuspended in 6 mL of RPMI, centri-
fuged at 850 g for 5 min then seeded at a density of
5 × 104 cells/well into ﬂat-bottomed, cell culture 96
well plates in a total volume of 100 μL per well. The
plates were incubated at 37°C, 5% CO2 for 24 h.
SDN/drugs at a concentration range up to 8 μg/mL
(each concentration was prepared in triplicate
treatment groups) were added and incubated at 37°C,
5% CO2 for a further 24 h. Positive (macrophages and
0.1% Triton (to indicate 100% of lysis of cells)) and
negative (macrophages and medium only) controls
were included in each plate. Following incubation, the
supernatant was removed, cells were washed twice
with 200 μL of PBS, and 0.1 mg/mL of Alamar Blue®
reagent was added to each well and incubated for a
ﬁnal 4 h at 37°C, 5% CO2, whereby ﬂuorescence was
read at an ex wavelength of 560 nm and an em
wavelength of 590 nm using a SpectraMax M5 plate
reader (USA). To determine if any SDN/drug interfer-
ence occurred, the 96 well plate was centrifuged at
850 g for 2 min, and the supernatant was removed
from each well and transferred into a fresh plate
and reread.
Infection of macrophages with pathogenic
Mycobacterium
Macrophages were detached from ﬂasks using TrypLE™
and centrifuged at 850 g for 2 min before seeding into
eight well chambered Permanox® slides (1 × 105
cells/well in a ﬁnal volume of 200 μL) and incubated
for 24 h at 37°C, 5% CO2. Supernatant was removed
from chambers, and cells were washed twice with
200-μL PBS. Map K10/GFP was cultured as described
previously, and 10 mL of bacterial culture (in the expo-
nential phase of growth) was centrifuged at 3090 g for
20 min and resuspended in 1 mL of PBS. The bacterial
cell suspension was then centrifuged for 5 min at
670 g to remove any residual antibiotic (from the 7H9)
and resuspended in 1 mL of PBS and passed through a
Gilson tip several times to reduce clumping.
Macrophages were infected with mycobacteria at a
multiplicity of infection (MOI) of 30:1, 10:1, and 5:1 in
complete medium (without streptomycin or penicillin)
at a ﬁnal volume of 200 μL per chamber (each MOI
was performed in triplicate) and incubated for 4 h at
37°C, 5% CO2. Supernatant was removed, and each
chamber was washed twice with 200 μL of PBS to
remove any residual/surface bound mycobacteria
before ﬁxing in 4% paraformaldehyde for 1 h. Control
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chambers were subject to the same procedures and
contained macrophages and medium only.
Imaging the uptake of SDNs by macrophages
Macrophages were prepared as outlined previously.
SDNs with DiD incorporated were added to eight well-
chambered Permanox® slides in complete medium
(without streptomycin or penicillin) at a concentration
range of 10–20 μg/mL in 200-μL ﬁnal volume (each con-
centration performed in triplicate) to Map K10/GFP-
infected and uninfected macrophages, which were
incubated for a further 4 h at 37°C, 5% CO2.
Supernatant was removed, and each chamber was
washed twice with 200 μL of PBS to remove any
residual/surface bound SDNs and/or mycobacteria
before ﬁxing using 4% paraformaldehyde for 1 h.
Control chambers contained macrophages and medium
only and macrophages with ﬂuorescent polystyrene
bead NPs in medium (Molecular Probes, USA)).
Staining and ﬁxed cell imaging of SDN treated
and infected macrophages
Following ﬁxation (using 4% paraformaldehyde for 1 h),
macrophages were stained with 40,6-diamidino-2-
phenylindole dihydrochlodire (DAPI) nuclear stain
(1:10 dilution in PBS). After 10 min, the slides were
washed twice with distilled water before being
mounted onto slides with Fluoro-Gel Mounting Medium
with TES Buffer solution (EMS, USA). Cellular uptake
was imaged using a Zeiss Axiovert 200M inverted Epi
ﬂuorescence microscope with an Axiocam MR3 camera
using objective magniﬁcations of 10×, 40×, 63×, and
100×. Cy3 (magenta, Ex/Em: 580/605 nm), Cy5
(yellow/red, Ex/Em: 596/670 nm), DAPI (blue, Ex/Em:
358⁄461 nm), GFP (green, Ex/Em: 488/507), and differ-
ential interference contrast or phase contrast channels
(depending on objective) were used. Images were proc-
essed using IMAGE-J (Fiji) software (Schindelin et al.
2012) and ZEISS AXIO VISION REL 4.8 software (Z-stacks),
thus showing the differential interference contrast
(grey), DiD incorporated SDNs (red (RIF) and yellow
(TRIPLE)), polyester beads (magenta), Map K10/GFP
(green), and macrophage nuclei (blue).
Results and Discussion
SDN manufacture and screening
Solid drug nanoparticles of the ﬁrst line TB antibiotics;
RIF, RIF + INH (DUAL) and RIF + INH + PZA (TRIPLE) were
synthesised and characterised via either an emulsion
template freeze dried or emulsion spray dried method
described previously (Giardiello et al. 2016; Zhang
et al. 2008). Drug loading, size, and Zeta potential of
the tested SDNs (in Middlebrooks 7H9 broth) are
provided in Tables 1a and 1b. We also adapted two of
the compounds (RIF and TRIPLE) to contain DiD
(Table 1a), for imaging purposes. The drug/drug ratio
of the loading was chosen to try and reﬂect what is used
clinically (TRIPLE SDN) but with respect to maximising
excipients wherever possible. A series of drug ratios
were initially produced, and the drug combination that
was the most reproducible was selected for this study.
Excipients were required to stabilise the prespray of
freeze drying, generally more excipient resulted in
smaller particles (conﬁrmed by DLS) by preventing
particle growth and agglomeration. Speciﬁc excipients
Table 1a. Drug types and drug loading (%).
Drug/SDN Total drug
loading (%)
Formulation
RIF (rifampicin aqueous drug) ≥97 Powder1 (stock suspension prepared with
methanol)
INH (isoniazid aqueous drug) ≥99 Powder2 (stock suspension prepared with
distilled water)
RIF SDN (rifampicin solid drug NP) 30 30% RIF/55% F68® Protect/15% Hyamine®
TRIPLE SDN (rifampin, isoniazid, and
pyrazinamide solid drug NP)
53.3 34% PZA/13% RIF/6% INH/40% Kollicoat®
Protect/7% Hyamine®
DUAL SDN (rifampin, isoniazid solid drug NP) 30 20% RIF/10% INH/60% Kollicoat® Protect/10%
Hyamine®
1Sigma-Aldrich
®
Product number R8883.
2Sigma-Aldrich
®
Product number I3377.
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(e.g., Pluronic F68®) were chosen based on their stabil-
ity, determined by DLS.
The Z-Average diameter (nm) readings for the SDNs
with DiD were larger than SDNs without the in-
corporated DiD dye, suggesting that those with the
DiD dye either agglomerated more readily, or the dye
incorporation increased the individual particle size
(Table 1b). No statistical difference of the Zeta
potential or dispersity was observed (Table 1b).
Stability tests were conducted to conﬁrm that RIF
was stable by employing p-XRD. Relative to crystalline
nonformulated RIF, RIF SDN was shown to be amor-
phous via p-XRD. Samples were stored for 4 weeks at
25°C and were shown to have remained amorphous
over this period and not regressed back to their crys-
talline forms (Figure S1).
To investigate the bactericidal activity of the SDN
formulations, as a surrogate for Mtb, we employed a
green ﬂuorescent protein (GFP) reporter strain of
Mycobacterium avium subsp. paratuberculosis (Map
K10/GFP) (Harris et al. 2002) permitting viability to be
monitored using ﬂuorescence. The antimycobacterial
properties of the SDN formulations and aqueous prepa-
rations of RIF and INH (solubilised per product instruc-
tions) were assessed using the previously described
assay (Donnellan et al. 2015). Viable Map K10/GFP
(2 × 106 cfu/mL) was exposed to SDNs and aqueous drugs
ranging in concentrations (0.001875–1.33 μg/mL) for
7 days. Following exposure to the SDNs the growth of
Map K10/GFP was inhibited in a dose-dependent and
time-dependent manner, but differing in efﬁcacy
between SDN types. The growth rates of Map K10/GFP
were expressed as the change in ﬂuorescence per day
(β) (Donnellan et al. 2015) and plotted against drug
concentration using the data modelling software
GRAPHPAD (GraphPad, Prism 5®). For each compound,
rather than comparing the total mass concentration
(for which mass includes polymer and/or surfactant),
the molar equivalent of drug loading for all three
SDNs was used (Fig. 1(A)). The IC50 was calculated
for each compound: RIF SDN 0.02 μg/mL, DUAL SDN
0.17 μg/mL, and TRIPLE SDN 0.02 μg/mL; RIF aqueous
1.06 μg/mL, INH aqueous did not show an effect and
therefore could not be calculated (potency ranking:
RIF SDN = TRIPLE SDN > DUAL SDN > RIF aq > INH aq).
All compounds, except INH, induced a dose-
dependent and time-dependent inhibition of Map
K10/GFP growth (Fig. 1(A)). RIF, the backbone of TB
therapy (Maartens and Wilkinson 2007; Longo et al.
2015; Laurenzo and Mousa 2011), as an SDN (containing
30% drug) was more inhibitory than aqueous RIF
(Fig. 1(B)). Figure 1(B) demonstrates that by ﬁtting the
data using a three-parameter sigmoidal model, the RIF
SDN exhibited improved potency (as demonstrated by
the net reduction in control growth rate, i.e., the
compound’s kill rate) as evidenced by a 50-fold reduced
IC50 value (0.02 μg/mL compared with 1.06 μg/mL)
observed for the aqueous formulation. The efﬁcacy
between compounds at different time points (from day
0 to day 7) shows that RIF can also elicit a faster kill rate
of Map K10/GFP when the drug is in the SDN form
compared with a conventional aqueous solution (Table
S1a,b). The INH formulated as the DUAL SDN, containing
10% INH and 20% RIF (Table 1a) or as an aqueous formu-
lation, had little impact on the growth of Map as previ-
ously reported (Fig. 1(A)) (Williams et al. 1999;
Krishnan et al. 2009). Although effective at killing Mtb
and M. bovis, this prodrug requires activation via the
product of the katG gene (catalase-peroxidase). This
gene is found in Map (Granger et al. 2004) but may be
down regulated in the K10/GFP strain, suggesting that
the INH content contributed a relatively small inhibi-
tory effect on mycobacteria growth (Fig. 1(A)). The
TRIPLE SDN, which contained 34% PZA, 13% RIF, and 6%
Table 1b. Dynamic light scattering (DLS).
SDN Z-Average (d.nm) Zeta potential (mV) PdI
RIF 36.75 ± 6.34 9.71 ± 0.38 0.77 ± 0.07
DUAL 40.73 ± 17.92 7.49 ± 0.49 0.37 ± 0.01
TRIPLE 161.78 ± 8.56 6.31 ± 0.86 0.31 ± 0.07
RIF + DiD 107.27 ± 32.93 10.46 ± 0.47 0.56 ± 0.09
TRIPLE + DiD 415.3 ± 64.81 10.43 ± 0.81 0.42 ± 0.03
Hydrodynamic diameter (Z-average), Zeta potential, and polydispersity index (PdI) of the SDN panel was assessed using DLS. Data expressed as mean ± SEM
(n = 6) (temperature: 25°C, dispersant: Middlebrooks 7H9 broth, concentration 100 μg/mL, pH 6.9, equilibrium time: 30 sec). With or without 1,10-
dioctadecyl-3,3,30,30-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD).
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INH (Table 1a) was as potent as the RIF SDN (IC50
0.02 μg/mL). PZA is activated at an acidic pH during
inﬂammation, and if phagocytosed by the macro-
phages, the SDN would be in an acidic environment.
However, assessment of Map growth was performed in
neutral conditions, which may suggest that this compo-
nent of the SDN was relatively inactive and RIF exerted
the dominant effect.
Infected macrophage SDN uptake
The next stage was to determine whether the SDNs
could trafﬁc to mycobacteria residing in macrophages.
Firstly, we checked that the SDNs and aqueous RIF were
not toxic to healthy macrophages (using the Alamar
Blue® assay). The SDNs and drugs tested did not signiﬁ-
cantly affect cell viability (P > 0.05 (Figure S2)). We
used ﬂuorescence imaging to demonstrate uptake of
both Map K10/GFP and SDNs and to determine if they
colocalised to the same intracellular location of the
cell. Macrophages were seeded (5 × 104 cells/well)
and infected with mycobacteria at an MOI of 5:1,
10:1, and 30:1, then treated with SDNs incorporating
DiD. Control experiments included macrophages only,
macrophages treated with nontoxic, ﬂuorescent
20 nm NP beads, and macrophages infected with Map
K10/GFP only (Fig. 2(A–D)). Washing removed extra-
cellular mycobacteria/SDNs/NPs beads prior to
imaging. Figure 2(E–F) illustrates the uptake of ﬂuo-
rescent versions of the RIF and TRIPLE SDNs by macro-
phages. Z-stacks conﬁrmed that RIF SDNs were
distributed throughout the cell, both within the cyto-
plasm and nucleus (Figure S3a–g). The TRIPLE SDNs,
being larger particles, appear to be agglomerated
(consistent with the DLS data) with limited uptake by
cells observed (Fig. 2(F)), which has been previously
reported (Clift et al. 2008). Overall, it appears that
SDNs remained as full, intact particles once engulfed
by macrophages.
To determine localisation relative to mycobacteria,
the ﬂuorescent SDNs were administered to Map
K10/GFP-infected macrophages. Figure 3(A) illustrates
macrophages infected with Map K10/GFP (MOI of 10)
treated with 20 μg/mL of RIF SDN. Both SDNs and
mycobacteria were observed to be intracellular. To
consolidate this ﬁnding, it was repeated with a lower
SDN concentration and Z-stack images taken (Fig. 3(B)).
The same test was carried out for the TRIPLE SDN
(Fig. 3(C,D)). The mycobacteria and SDN appear to be
colocalised for both SDN types, at least within the same
200-nm pixel area (the limit of image resolution).
(a)
(b)
Figure 1. Normalised, transformed data showing the growth of
Map K10/GFP grown in 7H9, in a microplate format, with SDNs
and aqueous antibiotics at different concentrations (0.001875–
1.33 μg/mL), normalised to the slope of the control where
β represents the change in ﬂuorescence (representing myco-
bacterial growth) per day. β was calculated through linear re-
gression analysis of the change in ﬂuorescence values over
time for each concentration (n ≥ 3). (B) Kill rate of RIF SDN
Vs RIF aqueous against Map K10/GFP. Emax curves showing
the relationship between the concentration of SDN or aqueous
RIF and their corresponding kill rates. The kill rate at each
concentration (0.001875–1.33 μg/mL) represents the net reduc-
tion in growth when compared to the corresponding control
(n ≥ 3).
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Because of the distance between GFP and far-red
excitation (Ex)/emission (Em) peaks, wavelength
crosstalk was unlikely to have occurred during the
imaging. However, GFP and far-red signal crosstalk
were tested for and found not to be occurring (Figure
S4a,b). Therefore, we are conﬁdent that colocalisation
of SDNs and mycobacteria does occur within
macrophages.
Figure 2. (A–F) Macrophage (J774A.1 murine macrophage cell line) treatments and infections. (DIC: grey, DAPI (nuclei): blue, NP beads
(CY3): magenta, GFP (Map): green, far-red CY5 (SDNs): red and yellow, at 63× (scale bars all 10 μM)). (A) Macrophages (not infected or
treated). (B) Macrophages treated with 10 μg/mL of NP beads. (C) Macrophages infected with Map K10/GFP at an MOI 5. (D) Macrophages
infected with Map K10/GFP at a MOI 10. (E) Macrophages treated with 10 μg/mL of RIF SDNs. (F) Macrophages treated with 10 μg/mL of
TRIPLE SDNs.
Intracellular delivery of nano-formulated anti-TB drugsSamantha Donnellan et al.
2017 | Volume 2 | Issue 3 |
Page 153
SDN versus aqueous drug intracellular potency
Our next objective was to determine the antimicrobial
effects of the SDN within the infected macrophages. A
preliminary study was carried out to compare the kill-
ing of Map K10/GFP by RIF SDN or aqueous RIF, within
macrophages. Infected macrophages (MOI 1:1, 10:1
and 30:1) were exposed to each treatment for 24 h then
lysed, and a phage ampliﬁcation assay (Rees and
Botsaris 2012) was performed. The results demon-
strated that the mycobacteria were being killed by
the drugs within the macrophages and that at an MOI
of 10:1 and 30:1, RIF SDN was more potent to intracel-
lular mycobacteria over the 24-h period than its
aqueous counterpart (Fig. 4). Although an exciting
initial result, further repeats in an intracellular model
is required to consolidate this ﬁnding.
Figure 3. (A–D) Infected macrophages treated with RIF SDNs. (DIC: grey, DAPI (nuclei): blue, GFP (Map): green, far-red CY5 (SDNs): red
and yellow, at 63× (scale bars all 10 μM)). (A) Map K10 GFP (MOI 10) infected macrophages following 4-h treatment with 20-μg/mL RIF
SDN. (B) 3D image of Map K10/GFP (MOI 10) infected macrophages following 4-h treatment with 10-μg/mL RIF SDN with Z-stacks resorted
using Zeiss Axio vision Rel 4.8. (C) Map/K10 GFP (MOI 10) infected macrophages following 4-h treatment with 10-μg/mLTRIPLE SDN where
the yellow signal is indicative of two overlapping ﬂuorescence signals, thus being indicative of colocalisation of SDNs and mycobacteria.
(D) Z-stack resorted of Figure 3(C) using Zeiss Axio vision Rel 4.8. The different angles of the Z-stacks display the orientation of Map K10/
GFP and further asserts the probable colocalisation of TRIPLE SDN and mycobacteria.
Figure 4. Phage ampliﬁcation assay. Each plaque formed on
soft agar represents one viable Map K10/GFP cell. Plaques
were manually counted for each treatment type, at each MOI,
following 24 h of treatment (each MOI carried out in triplicate,
n = 1).
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Conclusions
The main aims of novel drug discovery for TB are to
lower effective drug dose and shorten the treatment
period, which will consequently decrease costs and
likelihood of resistance. This work aimed to address
these factors. By working with FDA-approved drugs
(RIF, INH, and PZA), excipients from the Inactive
Ingredients Database (Kollicoat® protect, Hyamine®,
and Pluronic F68®) and synthesising formulations of
these drugs at the nano-scale, this approach may avoid
the vast costs and timescales normally associated with
novel drug development. Although SDNs would be
viewed as novel drugs by the Medicines and Healthcare
Products Regulatory Agency, as all the products are FDA
approved, progression to clinical studies may be fast
tracked. There are ongoing clinical trials of lopinavir
and Efavirenz SDNs to treat HIV (Eudract number
2013-004913-41), thus showing the feasibility and
potential of using SDNs to treat human diseases
(Giardiello et al. 2016).
In summary, we have presented evidence, which
shows that a nano-formulation of RIF is more effective
(50-fold) than the conventional aqueous drug at killing
a pathogenic Mycobacterium in vitro. We have veriﬁed
that mycobacteria-infected macrophages can engulf
SDNs, and both the drug and bacilli colocalise within
macrophages. Nano-dispersions of drugs could be a
more effective way of killing pathogens (Zhang et al.
2008; Choudhary and Kusum Devi 2015). Furthermore,
we have demonstrated that we can synthesise dual-
loaded and triple-loaded SDNs of FDA-approved anti-
TB ﬁrst line drugs, which would allow simultaneous
delivery of the drugs in the multidrug treatment
regime. Targeting drugs to macrophages, where the
bacilli reside, is an important consideration in treating
both active and latent TB infections because it can
increase antimicrobial efﬁciency (Wang et al. 2014;
Alexandru-ﬂaviu and Cornel 2014). Our studies suggest
that SDNs could offer an alternative, effective strat-
egy for treating TB. This has important implications
as it offers the potential to lower the dose and
shorten the duration of treatment. In turn, this could
lead to a reduction in treatment side effects and
slow down the emergence of multidrug-resistant
strains. Maintaining concentrations in target cells,
with lower systemic concentrations, may help miti-
gate drug-to-druginteractions (a major problem faced
when treating HIV and TB-coinfected patients)
through lower hepatic exposure. The application of
SDNs requires further investigation, but has the
potential to become invaluable in treating infectious
diseases worldwide.
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Figure S1 RIF SDN stability test over 4 weeks at 25°C.
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